The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system
Abstract
Background: This study aimed to measure the association of various H1-antihistamines (H1A) with Torsade de Pointes (TdP), and present a comprehensive overview of H1A-induced TdP cases reported to the Food and Drug Administration Adverse Event Reporting System (FAERS).Methods: All H1A-induced TdP cases (n = 406) were retrieved from the FAERS database using the preferred term ‘Torsade de Pointes’ of MedDRA version-22 from 1990 to 2019. Four data-mining algorithms were used for disproportionality analysis: Reporting Odds Ratio (ROR); Proportional Reporting Ratio (PRR), Empirical Bayes Geometric Mean (EBGM), and Information Content (IC). H1A with >3 TdP cases were included.Results: A total of 12 signals (Astemizole, cetirizine, chlorpheniramine, clemastine, desloratadine, diphenhydramine, hydroxyzine, loratadine, meclizine, promethazine, terfenadine, and trimeprazine) were identified including six new signals (cetirizine, chlorpheniramine, clemastine, desloratadine, loratadine, and meclizine). The number of risk factors (p = 0.031) and concomitant QT-prolonging drugs (p = <0.001) were significantly lower among new signals vs old signals. Moreover, new signals were strongly associated with QT-prolongation, cardiac reactions, and electrolyte abnormalities as compared with old signals.Conclusions: Our study found the increased torsadogenic potential of new signals compared with previously known old signals, hence necessitating clinical studies to determine the actual torsadogenic potential of newly identified signals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The study is designed as an observational, retrospective disproportionality analysis, a validated concept in pharmacovigilance to assess whether an association is likely to exist between semaglutide and gastrointestinal AEs.”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [16]
Citations
Cites
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V., Philippides, G. J., Roden, D. M., & Zareba, W. (2010) · Circulation · doi:10.1161/circulationaha.109.192704 · Cited by 821
Schwartz, P. J., & Woosley, R. L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.063 · Cited by 328 · cited 1×
“around 15,000 deaths have been attributed to noncardiac QTprolonging drugs [8].”
BackgroundDrug-induced QT interval prolongation: mechanisms and clinical management
Nachimuthu, S., Assar, M. D., & Schussler, J. M. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612454283 · Cited by 307
Torsade de Pointes Due to Noncardiac Drugs: Most Patients Have Easily Identifiable Risk Factors
Zeltser, D., Justo, D., Halkin, A., Prokhorov, V., Heller, K., & Viskin, S. (2003) · Medicine · doi:10.1097/01.md.0000085057.63483.9b · Cited by 273 · cited 1×
“The presence of at least one risk factor has been documented in almost all cases of TdP, while two or more risk factors have been reported in three-fourths of cases [18].”
BackgroundNon-cardiac QTc-prolonging drugs and the risk of sudden cardiac death
Straus, S. M. J. M., Sturkenboom, M. C. J. M., Bleumink, G. S., Dieleman, J. P., Lei, J. V. D., Graeff, P. A. D., Kingma, J. H., & Stricker, B. H. C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi312 · Cited by 260
Tisdale, J. E. (2016) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163516641136 · Cited by 209 · cited 1×
“The co-administration of QT-prolonging drugs may increase the risk of TdP due to drug–drug interactions [15,16].”
BackgroundEpidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany
Sarganas, G., Garbe, E., Klimpel, A., Hering, R. C., Bronder, E., & Haverkamp, W. (2013) · EP Europace · doi:10.1093/europace/eut214 · Cited by 160 · cited 1×
“the post-marketing withdrawal of many drugs [2,9] and since 1989, 14 clinically important drugs have been withdrawn from the market [9].”
BackgroundTaglialatela, M., Pannaccione, A., Castaldo, P., Giorgio, G., Zhou, Z., January, C. T., Genovese, A., Marone, G., & Annunziato, L. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.113 · Cited by 133 · cited 1×
“than the therapeutic one can cause 40% blockade of potassium channel thus causing QTIP and subsequent TdP [31].”
BackgroundDisproportionality methods for pharmacovigilance in longitudinal observational databases
Zorych, I., Madigan, D., Ryan, P. B., & Bate, A. (2011) · Statistical Methods in Medical Research · doi:10.1177/0962280211403602 · Cited by 128 · cited 1×
“a particular adverse event with drug results in a higher disproportionality score [22].”
Background
Research works printed but not linked: 7
- Li M, 2017, P T, 42, 473
- Martínez L, 2018, J Anal Pharm Res, 7, 197
- Kuo CC, 2000, Mol Pharmacol, 57, 135
- Martin LL, 2017, S D Med, 70, 135
- 2010, Prescrire Int, 19, 26
- Renard S, 2005, Arch Mal Coeur Vaiss, 98, 157
- 10.4196/kjpp.2009.13.3.215 · DOI
Cited by
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
Li, D., Chai, S., Wang, H., Dong, J., Qin, C., Du, D., Wang, Y., Du, Q., & Liu, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1259611 · Cited by 36
Bian, S., Li, L., Wang, Z., Cui, L., Xu, Y., Guan, K., Zhao, B., Wang, L., & Yin, J. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100594 · Cited by 27
Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis
Zhou, P., Jia, Q., Wang, Z., Zhao, R., & Zhou, W. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.940213 · Cited by 14
Li, N., Feng, Y., Chen, X., Li, Y., Zhang, C., & Yin, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1213608 · Cited by 11
Metadata
- Authors
- Ali, Z., Ismail, M., Khan, F., & Sajid, H.
- Affiliations
- University of Peshawar (PK)
- Corresponding author
- Ismail, Mohammad
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2020-11-13
- Volume
- 20
- Issue
- 1
- Pages
- 101-108
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W3095571268
- Cited by
- 21
- References
- 28
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 2 · 2021: 1
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Funders
- did not receive
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- histamine H1 receptor antagonists, torsades de pointes, drug-induced arrhythmia, QT prolongation, adverse drug reactions, disproportionality analysis, FDA Adverse Event Reporting System, drug safety signals, antihistamines, terfenadine, astemizole, diphenhydramine, loratadine, meclizine, clemastine, chlorpheniramine, desloratadine, citalopram
- MeSH terms
- Adolescent, Adult, Aged, Algorithms, Child, Child, Preschool, Female, Histamine H1 Antagonists, Humans, Infant, Long QT Syndrome, Male, Middle Aged, Risk Factors, United States, United States Food and Drug Administration, Torsades de Pointes, Databases, Factual, Adverse Drug Reaction Reporting Systems, Young Adult, Data Mining, Pharmacovigilance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system. https://app.cochat.ai/papers/10.1080/14740338.2021.1846717
- The paper
- Ali, Z., Ismail, M., Khan, F., & Sajid, H. (2021). Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2021.1846717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.